ERBB2 and breast carcinoma: In the NeoSphere trial, the addition of pertuzumab to trastuzumab and docetaxel resulted in significantly higher pCR rates 13, accelerating the approval of pertuzumab in the neoadjuvant treatment of HER2 positive breast cancer by the Food and Drug Administration (FDA) 14.